BioCentury
ARTICLE | Clinical News

Emricasan: Phase I data

February 16, 2015 8:00 AM UTC

An open-label, U.S. Phase I trial showed that a single dose of 50 mg oral emricasan led to no notable reductions in caspase-mediated biomarkers in patients with severe hepatic impairment or in healthy...